Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
Clinica Universidad de Navarra · Irmandade da Santa Casa de Misericórdia de São Paulo · +53 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
787
total citations
- FWCI
- 45.38
- Percentile
- 100%
- References
- 29
Citations per year
Authors
45- JFJesús F. San MiguelCorresponding
Clinica Universidad de Navarra
- VHVânia Hungria
Irmandade da Santa Casa de Misericórdia de São Paulo, Hospital São Paulo
- SYSung‐Soo Yoon
Seoul National University Hospital
- MBMeral Beksaç
Ankara University
- MΑMeletios Α. Dimopoulos
National and Kapodistrian University of Athens
Topics & keywords
Topics
Keywords
- Panobinostat
- Bortezomib
- Medicine
- Dexamethasone
- Multiple myeloma
- Placebo
- Clinical endpoint
- Internal medicine
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.